Pacific Shuanglin

Pacific Shuanglin Bio-pharmacy Co., Ltd. reports a **13% year-over-year decline in sales and revenue** for the nine months ended September 30, 2026, with figures dropping from **CNY 1,618.15 million** to **CNY 1,403.13 million**. The company’s earnings reflect a contraction in financial performance over the period. No additional operational or strategic details are provided in the announcement.

Oct 2026MarketScreenerNews article

Pacific Shuanglin Bio-pharmacy repurchases **12.85 million shares (1.36% of total)** for **CNY 138.14 million** under its April 2026 equity buyback plan. The company repurchased **2.30 million shares (0.25%) for CNY 22.17 million** between July and September 2026, marking the final tranche of the program. The buyback aligns with the firm’s capital allocation strategy amid ongoing pharmaceutical operations.

Oct 2026MarketScreenerNews article

Pacific Shuanglin Bio-Pharmacy Co., Ltd. announces a CNY 0.15 per share interim cash dividend for A shareholders, covering the first half of 2026. The dividend, approved at an Extraordinary General Meeting on September 9, 2026, totals CNY 1.50 per 10 shares after tax. Shareholders must be registered by October 22, 2026, for eligibility, with payments scheduled for October 23, 2026.

Sep 2026MarketScreenerNews article

Pacific Shuanglin Bio-Pharmacy Co., Ltd. proposes a CNY 0.15 per share interim cash dividend for the first half of 2026, totaling CNY 1.50 per 10 shares after tax. Shareholders will vote on the proposal at an Extraordinary General Meeting scheduled for September 9, 2026.

Aug 2026MarketScreenerNews article